Aurinia Pharmaceuticals Inc. (AUPH) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

63/ 100

GoAI Score

Buy

Valuation

91

Deep Value

Sentiment

64

Bullish

Risk

48

Elevated Risk

Momentum

48

Neutral

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CA
CEO: Kevin C. Tang
Listed since: Sep 3, 2014
Employees: 128

Market position

Day range

Current $16.11

$15.90$16.195

52-week range

Current $16.11

$10.34$19.25

Open: $16.11
Previous close: $16.25
Volume: 687.2K; 0.51× average
Average volume: 1.36M; Average daily volume
Market cap: 2.07B USD
Beta: 1.41; Market reference 1
50-day average: $15.8123; +1.88% above average
200-day average: $15.4991; +3.94% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 2.14B USD
P/E (TTM): 6.83×
P/B (TTM): 3.41×
P/S (TTM): 6.65×
EV / EBITDA: 16.73×
Earnings yield: 13.40%
Free cash flow yield: 6.32%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 90.36%
Operating margin: 48.39%
Net margin: 100.84%
Return on equity: 49.40%
Return on assets: 38.21%
Return on invested capital: 15.53%

Financial health

Debt / equity: 0.1×
Current ratio: 5.25×
Altman Z-score: 7.81
Piotroski F-score: 6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

283.06M USD+20.38%

Operating income

104.91M USD+109.6M USD

Net income

287.2M USD+4893.08%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	283.06M USD	235.13M USD	175.51M USD	134.03M USD	45.61M USD
Cost of goods sold	32.67M USD	28.25M USD	14.15M USD	5.66M USD	1.09M USD
Gross profit	250.39M USD	206.89M USD	161.37M USD	128.37M USD	44.51M USD
Research and development	32.51M USD	20.79M USD	49.64M USD	44.99M USD	51.14M USD
Selling, general, and administrative	101.79M USD	172.03M USD	195.04M USD	196.37M USD	171.44M USD
Operating expenses	145.48M USD	211.57M USD	253.06M USD	239.84M USD	225.25M USD
Interest income	13.57M USD	16.97M USD	17M USD	5.12M USD	529K USD
Interest expense	4.33M USD	4.84M USD	2.78M USD	—	—
Depreciation and amortization	9.27M USD	19.45M USD	11.65M USD	2.71M USD	2.76M USD
Operating income	104.91M USD	−4.69M USD	−91.69M USD	−111.47M USD	−180.74M USD
Net income	287.2M USD	5.75M USD	−78.02M USD	−108.18M USD	−180.97M USD

Company facts updated Sep 11, 2026.

Earnings

EPS beat rate: 73%; 8 beats, 3 misses, 0 met estimates
Average EPS surprise: +65.78%; 11 comparable reports
Latest EPS result: 0.28; Estimate 0.24 · Beat by 16.67%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Latest fiscal-year EPS: 2.07; FY2025 · +5167.18% year over year
Latest fiscal-year revenue: 283.06M USD; FY2025 · +20.38% year over year
Next fiscal-year EPS consensus: 0.944; FY2026 · 4 analysts
Next fiscal-year revenue consensus: 330.27M USD; FY2026 · 5 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$16.00

0.68% downside

Past 12 months12-month forecastHigh $16.00Average $16.00Low $16.00

Rating distribution

15 ratings

Strong buy00%

Buy1173%

Hold427%

Sell00%

Strong sell00%

Recent analyst actions

6 institutions

Leerink PartnersdowngradeOutperformMarket PerformDec 3, 2025

JefferiesupgradeHoldBuyNov 7, 2025

RBC Capital MktsdowngradeOutperformSector PerformNov 5, 2025

AUPH news

zacks.comAug 20, 2026

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

Read source

benzinga.comAug 20, 2026

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Read source

businesswire.comAug 19, 2026

Aurinia Settles Patent Litigation with Teva

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.

Read source

seekingalpha.comAug 12, 2026

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the…

Read source

zacks.comAug 6, 2026

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.

Read source

businesswire.comAug 6, 2026

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.

Read source